Smokeless Tobacco Use, Cigarette Smoking, and Upper Aerodigestive Tract Cancers: A Case-Control Study in the Batna Region, Algeria, 2008-2011

Messouda Oudjehi1,2, Isabelle Deltour3*, Mohamed Larbi Bouhidel1,2, Atika Bouhidel1,2, Abdelwahab Marref2, Véronique Luzon3, Joachim Schüz3*, Hocine Bounecel1 and Maria E Leon3

1Medical Faculty, Epidemiology and Preventive Medicine Department, University of Batna, Batna, Algeria. 2Cancer Registry of the Wilaya of Batna, University Hospital of Batna, Batna, Algeria. 3Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France.

ABSTRACT

BACKGROUND: A significant proportion of the Algerian population uses tobacco products and is at risk of developing tobacco-associated cancers.

AIMS: This case-control study reports on the association between tobacco use and the occurrence of upper aerodigestive tract (UADT) cancers in Batna, Algeria.

METHODS: Incident primary UADT cancer cases in residents of Batna in 2008-2011 were identified using the regional tumor registry. One hospital and 1 population control were matched to each case by sex, year of birth, and residence. Information on tobacco use was collected, and odds ratios (ORs) were obtained using conditional logistic regression also after sex stratification.

RESULTS: The study included 192 cases (80%) of the 241 primary UADT cancer cases identified and 384 controls. Males represented 76.6% of cancer cases. Cancers of the nasopharynx (48%) and the larynx (26%) were the most common types. Ever use of smokeless tobacco (ST) (OR = 1.0; 95% confidence interval [CI]: 0.6-1.5) or current ST use (OR = 1.1; 95% CI: 0.6-1.7) was not associated with overall risk of UADT cancers. Associations with cancers of the nasopharynx (OR = 1.5; 95% CI: 0.5-4.6) and oral cavity/oropharynx (OR = 3.0; 95% CI: 0.8-11.8) were found when comparing use of ST only to no consumption of any tobacco. Cigarette smoking was associated with an increase in the overall risk of UADT cancers, with a 3-fold increase in the risk of laryngeal cancer when comparing smoking only to no consumption of any tobacco (OR = 3.3; 95% CI: 1.0-11.5). Associations for smokers who also consumed ST differed by cancer site.

CONCLUSION: In this study from Algeria dominated by male cases and by cancer in the nasopharynx, cigarette smoking but not ST was associated with UADT cancer. Analyses by anatomical site and using as reference never use of any type of tobacco suggested few associations with ST but of lower precision.

KEYWORDS: Smokeless tobacco, chemma, neffa, smoking, upper aerodigestive tract cancers, Batna, Algeria

Introduction

Article 1 of the WHO Framework Convention on Tobacco Control defines tobacco products as “products entirely or partly made of the leaf tobacco as raw material which are manufactured to be used for smoking, sucking, chewing or snuffing.” In Algeria, chemma or shammah is the local term for moist snuff, which is placed directly on the gums or rolled in paper and then sucked in the mouth. Algerians also use dry snuff, called neffa, a product described as a powdered mixture containing tobacco leaf, calcium phosphate, and lime, which is sniffed or chewed.

The International Agency for Research on Cancer has classified smokeless tobacco (ST) as carcinogenic, with sufficient evidence that it causes cancers of the oral cavity, esophagus, and pancreas. The relationship between ST use and the development of upper aerodigestive tract (UADT) cancers has been investigated in several studies, some with conflicting results for specific anatomical sites. The evidence is limited by the low number of studies exploring cancer risk by anatomical site in the UADT, or in the head and neck, in association with ST use, a shortcoming probably explained by the large geographical variation in product composition and inherent health hazard. There are very few studies outside of India reporting on the association of ST use with cancer of the salivary glands, nasopharynx, hypopharynx, sinuses, larynx, and esophagus.

According to a 2005 Algerian nationwide survey, the prevalence of ST use was 9.5% (21.4% in men and 1.1% in women). The Algerian Adult Tobacco Survey of 2010, with respondents...
aged 15 to 74 years, generated an overall national estimate of current ST use of 5.3%, differing markedly between men (9.8%) and women (0.8%), and an overall prevalence of current tobacco smoking of 15.3% (27.1% in men and 1.7% in women). Daily smoking was reported by 17.6% of men and 0.9% of women. Thus, a significant proportion of the Algerian population uses tobacco regularly, including noncombustible forms, and is at risk of developing tobacco-associated cancers.

Objective
The objective of this study was to report on the relationship between ST use, cigarette smoking, and the occurrence of UADT cancers in the wilaya of Batna in 2008-2011 using a case-control design.

Methods
Study population
Cancer cases. The wilaya of Batna is an administrative region with an area of 12 000 km², located in the east of Algeria (latitude 35–36°N, longitude 4–7°E), with a population of 1 140 000 (2008 estimate) and the capital city of Batna. All patients, without age restrictions, who resided in the wilaya of Batna for at least 6 months and had been diagnosed with a primary UADT cancer between January 1, 2008, and December 31, 2011, were eligible to participate. The diagnosis was confirmed pathologically in cases using the International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) codes C00–C14 and C30–C32. All histological subtypes were included. Case identification was performed retrospectively for 2008-2009 and prospectively for 2010-2011. The Cancer Registry of the Wilaya of Batna was responsible for identifying incident cancers and for collecting demographic and histopathological data needed for the study. This population-based tumor registry, associated with the University Hospital of Batna, has been recording cancer cases for the population in the wilaya of Batna since 1995.

Information on cancer cases occurring in residents of the region of Batna who are diagnosed and treated elsewhere is obtained periodically by the registry through close collaboration with individual public and private health facilities outside of Batna. To avoid selective survival bias, deceased primary UADT cancer cases diagnosed in 2008-2011 were also included (n = 53). Patients with recurrence or metastasis and those whose primary tumor was diagnosed outside the study period were not eligible.

Controls. Two types of controls were matched to each case to assess potential selection effect that could have been associated with recruitment method. Hospital controls enrolled in the region’s hospitals were matched to cases by primary care center, sex and year of birth (± 5 years) among patients with eye diseases, or trauma, or those treated in the obstetric department of the 6 hospitals (the University Hospital of Batna and the hospitals of Arris, N’Gaous, Merouana, Barika, and Ain Touta; see hospitals’ locations on Supplemental Appendix Figure 1). The first patient who met the age and sex criteria of the case was interviewed.

The second control was selected from the general population by a random draw from the electoral roll of the Batna region for subjects older than 18 years. Controls younger than 18 years were drawn from the lists of pupils of the Algerian Education and Teaching Directorate. This was necessary because 2 cases younger than 18 years were included. The population controls were matched by sex, year of birth, and municipality of residence.

A total of 192 hospital controls and 192 population controls were interviewed, equal to the number of cases. Population controls who had moved since the last update of the electoral roll worked far away from their residential address, or refused to participate in the study were replaced. Overall, the identification of 289 population controls, including those with out-of-date addresses, working far away from their residence, and refusals, was necessary to interview 192 controls.

Data collection and consent procedure. Interviews with cases were conducted between 2010 and 2012 at the hospital or at home, and interviews with controls were conducted in 2011 and 2012 at the hospital (hospital controls) or most often at home (population controls). Information on lifestyle factors was collected using standardized questionnaires that were validated questionnaires from previous studies. Besides demographic data, ever snuff users and ever cigarette smokers...
were defined as subjects who had consumed $\geq 100\, \text{g}$ of snuff and smoked $\geq 100$ cigarettes, respectively, during their lifetime. Former users were those who had quit at least 1 year before the date of cancer diagnosis in cases. This date was used as a reference to assess former tobacco use status in matched controls. History of tobacco use was assessed, including age at which snuffing or smoking was initiated, type of snuffing or smoking, average number of grams of snuffing and average number of cigarettes per day, time since stopping, and duration of the habit in years. History of alcohol consumption recorded age at which drinking was initiated.

**Data analysis**

Exposure-effect relationships were reported on the basis of tobacco use status and duration of use, mean number of grams of ST used per day, and pack-years of cigarette smoking. The measures of association between exposure to various risk factors and cancers of the UADT overall were estimated including several subsites: nasopharynx (C11), oral cavity and oropharynx (C00-C06, C09, and C10), larynx (C32), and other UADT sites (C07, C08, C12, C13, C14, C30, and C31).

We performed conditional logistic regression analyses for matched sets to estimate odds ratios (OR) and their 95% confidence intervals (CI), combining the 2 control groups. We adjusted for potential confounders, namely ethnicity, education level, alcohol consumption, and mutually adjusted cigarette smoking status and ST use status. In subset analyses, the reference group was never users of any form of tobacco. In sensitivity analyses, we repeated the main analyses comparing cases to hospital controls and cases to community controls separately, we conducted sex-specific subsite analyses, and analyses of nasopharyngeal cancer (NPC) with additional adjustment on consumption of rancid fat because its consumption has been associated with this cancer in Algeria.3,17

**Results**

In total, 241 primary UADT cancer cases were identified, of which 192 were interviewed (80% participation rate). Nonresponse among cases was due to unknown address (n = 46) and refusals to participate (n = 3). The overall participation rate among population controls was 66%. Table 1 shows the characteristics of the study population.

We noted that the majority of the participants were either illiterate (49%) or poorly educated (32%). Subjects with all 4 grandparents of Berber origin accounted for nearly 65% of the study sample in cases and controls. The distribution of characteristics was the same in hospital controls and in population controls, except for alcohol consumption which was significantly more commonly reported by population controls than hospital controls (Table 1). Among male controls, ever ST use was not associated with smoking (36.8% ever ST users among never smokers and 42.4% among ever smokers, chi-square $P$ value = 0.3). However, smokers who ever consumed ST had used ST for shorter durations (25 years on average) than exclusive ST users (38 years on average, t-test $P$ value < .0005) and smokers had more often stopped ST consumption (87% former ST users among ever smokers vs 12% former ST users among never smokers, chi-square $P$ value < .0005). Women consumed very little tobacco, with six women only who reported ST use and 1 who reported smoking and ST use.

A total of 139 cancer cases (72%) were alive at the time of the interview (Table 2). Cancers of the nasopharynx were the largest group (48%), followed by cancers of the larynx (26%) and of the oral cavity and oropharynx (19%). Differentiated cell carcinoma was the most common histological type (59%), followed by undifferentiated cell carcinoma (32%). Cases were interviewed from the entire study region (Supplemental Appendix Figure 1).

Ever ST use was not associated with risk of UADT cancers (OR = 1.0; CI: 0.6-1.5) (Table 3). No differences in risk were observed with increasing duration of use or consumption.

We observed indications of an increase in the risk of UADT cancers with current smoking (OR = 1.4; CI: 0.8-2.4) and with increasing duration (20-40 years: $\text{OR} = 1.2$; CI: 0.6-2.2; > 40 years: $\text{OR} = 1.7$; CI: 0.9-3.2) (Table 4). We observed an increased risk of UADT cancers only with the largest smoking intensity and with exposure of $> 27$ pack-years compared with never smokers. However, there was a reduction in risk with a duration of $< 20$ years of smoking (OR = 0.5; CI: 0.2-1.0), with exposure of $< 10$ pack-years (OR = 0.5; CI: 0.2-0.9), and with $> 15$ years since stopping smoking compared with current smokers (OR = 0.4; CI: 0.2-0.9) (Table 4).

Table 5 shows ORs by cancer subsite in association with ST use and with cigarette smoking and by histology, in the nasopharynx. The associations did not appear to be the same in all UADT cancer sites; nevertheless, the OR tended to be similar for ST users who smoked compared with smokers who never consumed ST, except for laryngeal cancers. We observed an increase in the risk of NPC (Table 5) and of oral cavity cancer (Table 5) in exclusive ST users versus never consumers of tobacco, although neither estimate was statistically significant. Smoking was not associated with the risk of NPC overall (Table 5), and neither was it associated with the risk of oral cavity cancer (Table 5). For laryngeal cancer, exclusive use of ST was associated with a nonstatistically significant OR below 1, based on 1 exposed case, whereas the risk of laryngeal cancer in exclusive smokers was $3.3$ (95% CI: 1.0-11.5) compared with the small group of never tobacco-consumers (6 cases had never consumed tobacco) (Table 5). While numbers were too small for the analysis of differentiated nasopharyngeal cancer (Table 5), results for undifferentiated NPC were similar to the whole group (Table 5). Sensitivity analyses comparing cases to either the hospital controls or the community controls did not show major differences from the main results (data not shown in tables). Overall results were derived from the male population (Supplemental Appendix Table 1) suggesting an association between ST use and overall UADT cancer (OR = 1.3; 95%
Table 1. Characteristics of the study population in the case-control study of upper aerodigestive tract cancers in Batna, Algeria, 2008-2011.

| CHARACTERISTIC                              | CASES     | HOSPITAL CONTROLS | COMMUNITY CONTROLS | P VALUE* |
|--------------------------------------------|-----------|-------------------|--------------------|----------|
|                                            | N=192     | N=192             | N=192              |          |
|                                            | N %       | N %               | N %                |          |
| Sex                                        |           |                   |                    |          |
| Male                                       | 147       | 147               | 147                |          |
| Female                                     | 45        | 45                | 45                 |          |
| Age at interview (years)b                  |           |                   |                    |          |
| Average                                    | 57.2      | 57.4              | 57.9               | matched  |
| Standard Deviation                          | 16.8      | 17.0              | 16.8               |          |
| Range                                      | 11-94     | 14-97             | 12-95              |          |
| Education level                            | .95       |                   |                    |          |
| Illiterate                                 | 96        | 95                | 92                 | 47.9     |
| Primary/junior                             | 60        | 63                | 64                 | 33.4     |
| Secondary/university                       | 36        | 34                | 36                 | 18.7     |
| Marital status                             | .70       |                   |                    |          |
| Married                                    | 158       | 152               | 157                | 81.8     |
| Single                                     | 23        | 22                | 17                 | 8.9      |
| Divorced/widowed                           | 11        | 18                | 18                 | 9.4      |
| Ethnicity                                  | .85       |                   |                    |          |
| Berber                                     | 125       | 122               | 126                | 65.6     |
| Arab                                       | 54        | 55                | 50                 | 26.0     |
| Mixc                                       | 13        | 15                | 16                 | 8.3      |
| Longest occupation                         | .58       |                   |                    |          |
| Worker                                     | 108       | 112               | 108                | 56.2     |
| Farmer/artisan                             | 19        | 11                | 18                 | 9.3      |
| Intellectual/professional                  | 32        | 34                | 39                 | 20.3     |
| Retired/unemployed                         | 31        | 32                | 26                 | 13.5     |
| Unknown                                    | 2         | 1                 | 1                  |          |
| Use of smokeless tobacco                   | .24       |                   |                    |          |
| Never                                      | 134       | 124               | 139                | 72.3     |
| Former                                     | 26        | 32                | 27                 | 14.0     |
| Current                                    | 32        | 36                | 26                 | 13.5     |
| Smokeless tobacco types                    |           |                   |                    |          |
| Industrial, sucked                         | .55       |                   |                    |          |
| Never                                      | 151       | 143               | 148                | 77.1     |
| Ever                                       | 41        | 49                | 44                 | 22.9     |
| Artisanal, sucked                          | .19       |                   |                    |          |
| Never                                      | 170       | 173               | 180                | 93.8     |

(Continued)
CI: 0.6-3.1) of similar magnitude as that seen with smoking (OR = 1.3; 95% CI: 0.7-2.4) (Supplemental Appendix Table 1). The previously seen association between ST and oral cancer disappeared when considering males exclusively (27 of 37 cases). In women, an increased risk of UADT for ever tobacco consumption was found (OR = 3.5; 95% CI: 0.6-18.5) (Supplemental Appendix Table 2). In analyses of NPC, additional adjustment for rancid fat consumption did not modify the associations (data not shown in tables).

Discussion
Our study in Algeria is representative of all primary incident UADT cancers diagnosed in the wilaya. Notably, the cancer subsites included were a priori hypothesized to be most exposed to ST, and we did not only include anatomical sites known to be associated with ST use or with smoking.18-20

Most of the UADT cancer cases occurred in men. With the exception of 1 female case, all laryngeal cancers were diagnosed in men. For the other cancer sites, more than two thirds were male cases. This is in contrast to more developed countries, where more and more women are being diagnosed with these types of cancers, with the exception of nasopharyngeal cancer, which is rare in Europe and North America.21,22

In our study, ever or current use of ST was not associated with overall risk of UADT cancer. No trends of increasing risk were detected with duration or intensity of ST use. The most commonly affected UADT site was the nasopharynx. We observed a nonsignificant association between exclusive ST use and NPC, compared with never users of tobacco, based on small numbers. In a study from the Maghreb, Feng et al3 showed that snuff sucking was associated with an increased risk of differentiated NPC but not of undifferentiated carcinoma.

This study provides some evidence of an association between ST use and oral cavity cancers after adjusting for cigarette smoking and alcohol consumption, based on small numbers. ST use has previously been linked with the risk of

Table 1. (Continued)

| CHARACTERISTIC                      | CASES N=192 | HOSPITAL CONTROLS N=192 | COMMUNITY CONTROLS N=192 | P VALUE* |
|------------------------------------|-------------|-------------------------|--------------------------|----------|
|                                    | N           | %                       | N                        | %        |
| Ever                               |             |                         |                          |          |
| Industrial, snuff                  |             |                         |                          |          |
| Never                             | 186         | 96.9                    | 179                      | 93.2     | 187      | 95.8     | .09      |
| Ever                              | 6           | 3.1                     | 13                       | 6.8      | 5        | 2.6      |
| Artisanal, snuff                   |             |                         |                          |          |
| Never                             | 190         | 99.0                    | 189                      | 98.4     | 192      | 100.0    | .25      |
| Ever                              | 2           | 1.0                     | 3                        | 1.6      | 0        | 0.0      |
| Smoking                            |             |                         |                          |          |
| Never                             | 83          | 43.2                    | 84                       | 43.8     | 85       | 44.3     | .10      |
| Former                            | 58          | 30.2                    | 75                       | 39.1     | 59       | 30.7     |
| Current                           | 51          | 26.6                    | 33                       | 17.2     | 48       | 25.0     |
| Alcohol consumption               |             |                         |                          |          |
| Never                             | 162         | 84.4                    | 167                      | 87.0     | 149      | 77.6     | .02      |
| Ever                              | 30          | 15.6                    | 25                       | 13.0     | 43       | 22.4     |
| Consumption of rancid fat         |             |                         |                          |          |
| Never                             | 56          | 29.5                    | 42                       | 21.9     | 56       | 29.2     | .10      |
| Ever                              | 136         | 70.5                    | 150                      | 78.1     | 136      | 70.8     |
| Respondents                       | 62          | 32.3                    | 6                        | 3.1      | 12       | 6.3      | .15      |

*Chi-square or Fisher exact test comparing hospital and population controls.
Information missing for 3 cases and 3 hospital controls.
At least 1 Arab grandparent and 1 Berber grandparent.
premalignant lesions in the oral cavity and with an excess risk of oral cancers.\textsuperscript{5}

We unexpectedly observed a reduced risk of laryngeal cancer in exclusive ST users versus never users of tobacco, which could be associated with statistical fluctuations associated to the small sample size in the reference and the exclusive ST user group or with recall bias, especially in view of the relatively higher proportion of proxy interviews of deceased cases. However, the larynx is a site for which conflicting results have been reported in association with ST use. The study of Sapkota et al\textsuperscript{18} did not find an association between laryngeal cancer and ST use in India, while a recent meta-analysis including studies in India reported a nonsignificant increase in risk (OR = 1.79; CI: 0.70--4.54).\textsuperscript{7} Given the differences in the types of products

Table 2. Description of cancer cases in the study of upper aerodigestive tract cancers in Batna, Algeria, 2008-2011.

| CHARACTERISTIC                  | NASOPHARYNGEAL CANCER\textsuperscript{a} | ORAL CAVITY CANCER\textsuperscript{b} | LARYNGEAL CANCER\textsuperscript{c} | OTHER UADT CANCERS\textsuperscript{d} | TOTAL |
|--------------------------------|------------------------------------------|--------------------------------------|-------------------------------------|----------------------------------------|-------|
|                                | N = 92                                   | N = 37                                | N = 50                              | N = 13                                  | N = 192 |
|                                | N (%)                                    | N (%)                                 | N (%)                               | N (%)                                  | N (%)  |
| Sex                            |                                          |                                      |                                     |                                        |       |
| Male                           | 63 (68.5)                                | 27 (73.0)                             | 49 (98.0)                           | 8 (61.5)                               | 147 (76.6) |
| Female                         | 29 (31.5)                                | 10 (27.0)                             | 1 (2.0)                             | 5 (38.5)                               | 45 (23.4) |
| Age at diagnosis (years)       |                                          |                                      |                                     |                                        |       |
| Average (Standard Deviation)   | 48.7 (15.8)                              | 65.0 (15.3)                           | 62.3 (12.3)                         | 49.7 (21.6)                            | 55.4 (16.9) |
| Range                          | 10-86                                    | 28-94                                 | 33-86                               | 19-81                                  | 10-94  |
| Distribution of age at diagnosis (years)\textsuperscript{e} |                                          |                                      |                                     |                                        |       |
| 0-19                           | 7 (7.9)                                  | 0 (0.0)                               | 0 (0.0)                             | 1 (7.7)                                | 8 (4.3)  |
| 20-39                          | 13 (14.6)                                | 2 (5.6)                               | 2 (4.2)                             | 4 (30.8)                               | 21 (11.3) |
| 40-59                          | 47 (52.8)                                | 12 (33.3)                             | 17 (35.4)                           | 3 (23.1)                               | 79 (42.5) |
| 60-79                          | 20 (22.5)                                | 16 (44.4)                             | 25 (52.1)                           | 4 (30.8)                               | 65 (34.9) |
| 80+                            | 2 (2.2)                                  | 6 (16.7)                              | 4 (8.3)                             | 1 (7.7)                                | 13 (7.0)  |
| Vital status                   |                                          |                                      |                                     |                                        |       |
| Alive                          | 69 (75.0)                                | 29 (78.4)                             | 34 (68.0)                           | 7 (53.8)                               | 139 (72.3) |
| Dead                           | 23 (25.0)                                | 8 (21.6)                              | 16 (32.0)                           | 6 (46.2)                               | 53 (27.6) |
| Histology                      |                                          |                                      |                                     |                                        |       |
| Squamous cell carcinoma, differentiated | 22 (23.9) | 36 (97.3) | 47 (94.0) | 9 (69.2) | 114 (59.3) |
| Nonkeratinizing cell carcinoma, undifferentiated | 61 (66.3) | 0 (0.0) | 0 (0.0) | 1 (7.7) | 62 (32.2) |
| Other histological types       | 3 (3.3)                                  | 0 (0.0)                               | 0 (0.0)                             | 3 (23.1)                               | 6 (3.1)  |
| Unknown\textsuperscript{f}     | 6 (6.5)                                  | 1 (2.7)                               | 3 (6.0)                             | 0 (0.0)                                | 10 (5.2)  |
| Year of diagnosis              |                                          |                                      |                                     |                                        |       |
| 2008                           | 21 (22.8)                                | 11 (29.7)                             | 13 (26.0)                           | 5 (38.5)                               | 50 (26.4) |
| 2009                           | 29 (31.5)                                | 5 (13.5)                              | 11 (22.0)                           | 1 (7.7)                                | 46 (23.9) |
| 2010                           | 22 (23.9)                                | 14 (37.8)                             | 12 (24.0)                           | 4 (30.8)                               | 52 (27.0) |
| 2011                           | 20 (21.7)                                | 7 (18.9)                              | 14 (28.0)                           | 3 (23.1)                               | 44 (22.9) |

\textsuperscript{a}Nasopharyngeal cancer: ICD-10 code C11; any morphology code.
\textsuperscript{b}Oral cavity cancer: ICD-10 codes C00-C06, C09, and C10; any morphology code.
\textsuperscript{c}Laryngeal cancer: ICD-10 code C32; any morphology code.
\textsuperscript{d}Other cancers: ICD-10 codes C07, C08, C12, C13, C30, and C31; any morphology code.
\textsuperscript{e}Information missing for 1 oral cavity, 3 nasopharyngeal, and 2 laryngeal cancer cases.
\textsuperscript{f}Information could not be obtained.
available, patterns of use, and associated risks, there may be substantial differences between regions and countries in the burden of laryngeal cancer attributable to ST use.

Ever and current cigarette smoking were associated with a modest increase in the overall risk of UADT cancers in the wilaya of Batna, although the ORs were not statistically significant. While the ORs tended to be higher in association with the longest duration of smoking or the highest number of cigarettes smoked daily, the trend of increasing risk with increasing exposure was seen only with cumulative exposure in pack-years. In agreement with the established reduction in risk after quitting smoking,23 former smokers with >15 years of abstinence had a reduced risk of UADT cancers. We observed a decreased risk of UADT cancers in association with exposure of <10 pack-years of cigarette smoking and with smoking duration of <20 years. These reduced risks for the lowest categories of the smoking metrics might be due to recall or reporting bias from inaccurate disclosure of smoking status of cases classified as never smokers, inaccurate reporting of duration and intensity of smoking among light smokers, a complex relationship with ST, lacking or insufficient adjustment for additional risk factors, or random fluctuation due to small numbers.

Although smoking is recognized as a cause of NPC,5 we did not detect an association between smoking and risk of NPC, overall or for the undifferentiated carcinoma type in this

| CHARACTERISTIC                                      | CASES | CONTROLS | CRUDE OR< | ADJUSTED ORb |
|-----------------------------------------------------|-------|----------|-----------|--------------|
| Smokeless tobacco use                                |       |          |           |              |
| Never                                               | 134   | 69.8     | 263       | 68.5         | 1            | 1            |
| Ever                                                | 58    | 30.2     | 121       | 31.5         | 0.9          | 0.6-1.4      | 1.0          | 0.6-1.5      |
| Current status of smokeless tobacco use              |       |          |           |              |
| Never                                               | 134   | 69.8     | 263       | 68.5         | 1            | 1            |
| Former                                              | 26    | 13.5     | 59        | 15.4         | 0.8          | 0.5-1.4      | 0.9          | 0.5-1.6      |
| Current                                             | 32    | 16.7     | 62        | 16.1         | 1.0          | 0.6-1.6      | 1.1          | 0.6-1.7      |
| Duration of smokeless tobacco use (years)            |       |          |           |              |
| Never                                               | 134   | 71.2     | 263       | 68.7         | 1            | 1            |
| <20                                                 | 23    | 12.3     | 40        | 10.4         | 1.1          | 0.6-1.9      | 1.2          | 0.7-2.2      |
| 20-40                                               | 14    | 7.5      | 42        | 11.0         | 0.6          | 0.3-1.2      | 0.6          | 0.3-1.3      |
| >40                                                 | 16    | 8.6      | 38        | 9.9          | 0.8          | 0.4-1.5      | 0.8          | 0.4-1.5      |
| Unknown                                             | 5     | 1        | —         | —            | —            | —            |
| Smokeless tobacco consumption (g/day)                |       |          |           |              |
| Never                                               | 134   | 72       | 263       | 68.7         | 1            | 1            |
| <7                                                  | 18    | 9.7      | 40        | 10.4         | 0.9          | 0.5-1.6      | 0.9          | 0.5-1.7      |
| 7-15                                                | 17    | 9.1      | 41        | 10.7         | 0.8          | 0.4-1.4      | 0.8          | 0.4-1.5      |
| >15                                                 | 17    | 9.2      | 39        | 10.2         | 0.8          | 0.4-1.6      | 0.9          | 0.5-1.7      |
| Unknown                                             | 6     | 1        | —         | —            | —            | —            |
| Types of smokeless tobacco                           |       |          |           |              |
| Never                                               | 134   | 69.8     | 263       | 68.5         | 1            | 1            |
| Exclusively industrial                               | 35    | 18.2     | 87        | 22.7         | 0.8          | 0.5-1.2      | 0.8          | 0.5-1.3      |
| Artisanal with or without industrial                | 23    | 12.0     | 34        | 8.9          | 1.3          | 0.7-2.4      | 1.4          | 0.7-2.6      |

<sup>a</sup>Crude ORs obtained from the conditional logistic regression analyses for matched sets.<br> <sup>b</sup>Adjusted ORs were additionally adjusted for cigarette smoking, education level, alcohol consumption, and ethnicity.
Table 4. Cigarette smoking and risk of upper aerodigestive tract cancers; odds ratios (ORs) and 95% confidence intervals (95% CIs) obtained using conditional logistic regression analyses, Batna, Algeria, 2008-2011.

| CHARACTERISTIC                              | CASES | CONTROLS | CRUDE OR<sup>a</sup> | ADJUSTED OR<sup>b</sup> |
|---------------------------------------------|-------|----------|-----------------------|--------------------------|
|                                             | N     | %       | N     | %       | OR 95% CI | OR 95% CI |
| Cigarette smoking status                    |       |         |       |         |           |           |
| Never                                       | 83    | 43.2    | 169  | 44.0    | 1         | 1         |
| Ever                                        | 109   | 56.8    | 215  | 56.0    | 1.0       | 0.7-1.7   | 1.1       | 0.7-1.8   |
| Current status of cigarette smoking        |       |         |       |         |           |           |
| Never                                       | 83    | 43.2    | 169  | 44.0    | 1         | 1         |
| Former                                      | 58    | 30.2    | 134  | 34.9    | 0.9       | 0.5-1.5   | 0.9       | 0.5-1.5   |
| Current                                     | 51    | 26.6    | 81   | 21.1    | 1.3       | 0.8-2.2   | 1.4       | 0.8-2.4   |
| Duration of cigarette smoking (years)      |       |         |       |         |           |           |
| Never                                       | 83    | 43.5    | 169  | 44.0    | 1         | 1         |
| <20                                         | 20    | 10.5    | 74   | 19.3    | 0.5       | 0.3-1.0   | 0.5       | 0.3-1.0   |
| 20-40                                       | 50    | 26.2    | 89   | 23.2    | 1.1       | 0.6-2.0   | 1.2       | 0.6-2.2   |
| >40                                         | 38    | 19.9    | 52   | 13.5    | 1.6       | 0.9-3.0   | 1.7       | 0.9-3.2   |
| Unknown                                     | 1     |          |       |         |           |           |
| Intensity of smoking (cigarettes per day)   |       |         |       |         |           |           |
| Never                                       | 83    | 45.4    | 169  | 44.1    | 1         | 1         |
| 0-9                                         | 18    | 9.8     | 67   | 17.5    | 0.5       | 0.3-1.1   | 0.5       | 0.3-1.0   |
| 10-20                                       | 42    | 23.0    | 96   | 25.1    | 0.9       | 0.5-1.6   | 0.9       | 0.5-1.6   |
| >20                                         | 40    | 21.9    | 51   | 13.3    | 1.6       | 0.8-2.6   | 1.8       | 0.9-3.3   |
| Unknown                                     | 9     |          |       |         |           |           |
| Cigarette smoking exposure (pack-years)     |       |         |       |         |           |           |
| Never                                       | 83    | 45.4    | 169  | 44.1    | 1         | 1         |
| <10                                         | 17    | 9.3     | 66   | 17.2    | 0.5       | 0.2-1.0   | 0.5       | 0.2-0.9   |
| 10-27                                       | 22    | 12.0    | 71   | 18.5    | 0.6       | 0.3-1.2   | 0.6       | 0.3-1.2   |
| >27                                         | 61    | 33.3    | 77   | 20.1    | 1.7       | 0.9-2.9   | 1.8       | 1.0-3.3   |
| Unknown                                     | 9     |          |       |         |           |           |
| Age at starting cigarette smoking (years)   |       |         |       |         |           |           |
| Never                                       | 83    | 44.1    | 169  | 44.1    | 1         | 1         |
| <14                                         | 23    | 12.2    | 49   | 12.8    | 0.6       | 0.3-1.2   | 1.0       | 0.5-1.9   |
| 14-23                                       | 73    | 38.8    | 136  | 35.5    | 0.7       | 0.4-1.4   | 1.0       | 0.6-1.8   |
| >23                                         | 9     | 4.8     | 29   | 7.6     | 1.3       | 0.7-2.2   | 0.5       | 0.2-1.4   |
| Unknown                                     | 4     |          |       |         |           |           |
| Time since cigarette smoking cessation (years) |     |         |       |         |           |           |
| Current smoker                              | 51    | 26.6    | 81   | 21.1    | 1         | 1         |
| <15                                         | 38    | 19.8    | 58   | 15.1    | 1.0       | 0.5-1.8   | 1.1       | 0.6-2.1   |
| >15                                         | 20    | 10.4    | 76   | 19.8    | 0.4       | 0.2-0.8   | 0.4       | 0.2-0.9   |

<sup>a</sup>Crude ORs obtained from the conditional logistic regression analyses for matched sets.

<sup>b</sup>Adjusted ORs were additionally adjusted for smokeless tobacco use status, education level, alcohol consumption, and ethnicity.
Table 5. Smokeless tobacco use, cigarette smoking, and risk of site-specific UADT cancers; odds ratios (ORs) and 95% confidence intervals (95% CIs) obtained using conditional logistic regression analyses, Batna, Algeria, 2008-2011: nasopharynx, oral cavity/oropharynx, larynx, differentiated nasopharynx, and undifferentiated nasopharynx cancers.

| TOBACCO USE                  | CASES | %  | CONTROLS | %  | CRUDE ORa | 95% CI     | ADJUSTED ORa | 95% CI     |
|------------------------------|-------|----|----------|----|------------|------------|--------------|------------|
| Nasopharyngeal cancer (all, N=276) |       |    |          |    |            |            |              |            |
| Never                        | 42    | 46 | 83       | 45 | 1.0        | 1          |              |            |
| Ever cigarette smoker, never smokeless tobacco user | 26    | 28 | 59       | 32 | 0.8        | 0.4        | -1.8         | 0.3        |
| Never cigarette smoker, ever smokeless tobacco user  | 10    | 11 | 11       | 6  | 1.8        | 0.6        | -5.2         | 0.5        |
| Cigarette smoker and smokeless tobacco user           | 14    | 15 | 31       | 17 | 0.8        | 0.3        | -2.1         | 0.3        |
| Oral cavity cancer (N=111) |       |    |          |    |            |            |              |            |
| Never                        | 10    | 27 | 26       | 35 | 1.0        | 1          |              |            |
| Ever cigarette smoker, never smokeless tobacco user  | 9     | 24 | 20       | 27 | 1.2        | 0.3        | -4.7         | 0.3        |
| Never cigarette smoker, ever smokeless tobacco user  | 8     | 22 | 8        | 11 | 2.9        | 0.8        | -11.2        | 0.8        |
| Cigarette smoker and smokeless tobacco user           | 10    | 27 | 20       | 27 | 1.4        | 0.4        | -5.0         | 0.4        |
| Laryngeal cancer (N=150)    |       |    |          |    |            |            |              |            |
| Never                        | 6     | 12 | 20       | 20 | 1.0        | 1          |              |            |
| Ever cigarette smoker, never smokeless tobacco user  | 31    | 62 | 36       | 36 | 3.6        | 1.1        | -11.9        | 1.0        |
| Never cigarette smoker, ever smokeless tobacco user  | 1     | 2  | 8        | 8  | 0.4        | 0.0        | -4.3         | 0.0        |
| Cigarette smoker and smokeless tobacco user           | 12    | 24 | 36       | 36 | 1.4        | 0.4        | -4.6         | 0.4        |
| Nasopharyngeal cancer of differentiated cell carcinoma typeb(N=66) |       |    |          |    |            |            |              |            |
| Never                        | 7     | 32 | 15       | 34 | 1.0        | —          | —            | —          |
| Ever cigarette smoker, never smokeless tobacco user  | 8     | 36 | 16       | 36 | 1.5        | 0.1        | -15.7        | —          |
| Never cigarette smoker, ever smokeless tobacco user  | 2     | 9  | 4        | 9  | 1.4        | 0.1        | -20.8        | —          |
| Cigarette smoker and smokeless tobacco user           | 5     | 23 | 9        | 20 | 1.6        | 0.1        | -19.1        | —          |
| Nasopharyngeal cancer of undifferentiated cell carcinoma typeb (N=183) |       |    |          |    |            |            |              |            |
| Never                        | 30    | 49 | 61       | 50 | 1.0        | 1          |              |            |
| Ever cigarette smoker, never smokeless tobacco user  | 17    | 28 | 36       | 30 | 0.9        | 0.3        | -2.4         | 0.3        |
| Never cigarette smoker, ever smokeless tobacco user  | 5     | 8  | 5        | 4  | 2.1        | 0.5        | -8.7         | 0.4        |
| Cigarette smoker and smokeless tobacco user           | 9     | 15 | 20       | 16 | 0.9        | 0.3        | -2.9         | 0.2        |

*aCrude ORs obtained from the conditional logistic regression analyses for matched sets, and adjusted ORs were additionally adjusted for education level, alcohol consumption, and ethnicity.

*bThree cases of nasopharyngeal lymphoma and 6 cases with unknown histology were not included.

*cNo reliable estimate available due to small numbers.
population of mainly Berber ethnicity. Few studies have reported epidemiological findings of NPC by histology in association with smoking.\textsuperscript{24,25} In the study of Polesel et al\textsuperscript{23} in a low-risk population, current smoking was associated with a nonsignificant increase of overall NPC, while an increased risk was observed for differentiated NPC. In one study from the Maghreb, a region of intermediate NPC incidence,\textsuperscript{26} Feng et al\textsuperscript{20} reported a similar pattern in populations of predominantly Arab ethnicity. Two meta-analyses found a stronger association with smoking in low-risk populations and with differentiated NPC than with undifferentiated NPC.\textsuperscript{20,27} However, NPC has been associated with smoking-related reactivation of Epstein-Barr virus infection in China, an area with high NPC incidence, in a study of almost exclusively undifferentiated carcinomas.\textsuperscript{26,29} The lack of an effect of smoking on NPC risk in the current study may be due to possible different etiologies for the 2 histological types, with smoking being more strongly associated with the histology less prevalent in our NPC population. Socioeconomic differences between cases and controls not accounted for entirely by education level, such as income, may have also played a role in the results we observed. Our findings point to the importance of separating undifferentiated and differentiated NPC in analyses exploring exposure to tobacco with larger samples.

Our study detected a modest increase in the risk of oral cancer with smoking albeit nonsignificant in this population consuming very little alcohol. We found a marked increase in the risk of laryngeal cancer with ever smoking after adjusting for alcohol consumption, education level, and ethnicity. The magnitude of the association is lower than risk estimates obtained in countries on other continents.\textsuperscript{5} Lower level of alcohol consumption and intensity and duration of smoking may account for differences in the strength of the association we report in our study.

This is the first case-control study in Algeria investigating UADT cancers and the use of ST as marketed and consumed in the wilaya of Batna. The use of ST is a rooted tradition in Algeria, particularly in men. This study benefited from the collection of detailed information on other risk factors, such as alcohol consumption; this made it possible to adjust for this risk factor for UADT cancers, which is also associated with ST use and tobacco smoking. Our study is based on a high response rate in both cases and controls.

Despite the strengths of this study, it has limitations: the small number of cases by UADT subsite conditioned our analysis because the statistical power to assess the effects of ST use was low when anatomical subsites were analyzed; therefore, it was not feasible to completely disentangle if ST use was a primary or secondary factor compared with smoking for the various cancers studied. Due to its retrospective nature, the possibility of recall bias and uncertainties in exposure assessment also remained. Population controls are preferable to hospital control but this study design complicates the data collection. In our study, the risk factor profile of hospital controls was in between that of cases and population controls and only small differences between the series of controls were apparent; these are unlikely to have played a major role in the findings. Interviews were conducted face to face and as far as possible in person, avoiding the presence of another person, to attempt to limit reporting biases in culturally sensitive lifestyle habits such as alcohol consumption or smoking for women. Accuracy of reporting could have been affected by interviewing proxy respondents. However, it should be noted that the study questionnaire was presented to participants as part of a general health study, and for many of the associations explored, the distribution of the factors was similar in both cases and controls.

Cancer is an increasing public health problem in the Algerian population. UADT cancers tend to be diagnosed at an advanced stage, highlighting the importance of educating the general population about the harmful effects of ST use and tobacco smoking, even in the presence of other risk factors. The effectiveness of prevention depends partially on the identification of the risk factors that may be involved locally in the occurrence of cancer. In our study, ST use was suggestive of an increased risk of oral cancer and of NPC, and an increased risk of UADT cancers was observed with the longest duration and cumulative exposure to smoking, with a 3-fold increase in the risk of laryngeal cancer. These findings deserve follow-up in locally conducted larger case-control studies. Characterization of the diversity and composition of locally available ST products would be relevant to etiological studies and also provide useful evidence to advocate for healthier, tobacco-free lifestyles.

Conclusion

While ST use was not associated with overall risk of UADT cancers, associations with cancers of the nasopharynx and the oral cavity/oropharynx were obtained. This study suggests that the association between ST use, cigarette smoking, and UADT cancers differed among the nasopharynx, larynx, and oral cavity and oropharynx anatomical sites, but numbers for subsites were small.

Acknowledgements

The authors are grateful for the collaboration of the patients and the controls who agreed to participate in the study, the Hospital Directors of the services in which the study took place, the medical doctors in charge of prevention in the wilaya of Batna, and especially Dr. Gasmii Abderezak, Mr. Ben Yahia Wahid, and Ms. Amrani Khoukha, for helping with the selection of the controls, the Directors of the Land Use and Planning Authority, the employees of Batna's anticancer center and ENT department, and the registrars of the municipalities of the wilaya of Batna. The authors thank Ms Tracy Lignini (IARC) and Dr. Karen Muller (IARC) for their careful editing of the manuscript, and M. Liacine Bouaoun for the production of the map. Where authors are identified as personnel of the International Agency...
for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer / World Health Organization.

Author Contributions
MO and HB designed the study in collaboration with ID and JS. MEL and MO conducted the field work in collaboration with MLB, AB. AM, MO and VL performed the data management. MO performed the statistical analyses in collaboration with ID and JS. MEL and MO wrote the first draft of the manuscript. All authors commented on the manuscript and read and approved the final version.

ORCID iDs
Isabelle Deltour https://orcid.org/0000-0002-6602-6292
Joachim Schüz https://orcid.org/0000-0001-9687-2134

Supplemental Material
Supplemental material for this article is available online.

REFERENCES
1. World Health Organization. WHO Framework Convention on Tobacco Control. Geneva: World Health Organization; 2003.
2. Siddiqui K, Shah S, Abbas SM, et al. Global burden of disease due to smokeless tobacco consumption in adults: analysis of data from 113 countries. BMC Med. 2015;13:194.
3. Feng BJ, Khayati M, Ben-Ayoub W, et al. Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer. 2009;101:1207-1212.
4. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 89: Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamines. Lyon, France: IARC; 2007.
5. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100E: Personal Habits and Indoor Combustion. Lyon, France: IARC; 2012.
6. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Cancer Epidemiol. 2008;32:667-675.
7. Sinha DN, Abdulkader RS, Gupta PC. Smokeless tobacco-associated cancers: a systematic review and meta-analysis of Indian studies. Int J Cancer. 2016;138:1168-1179.
8. Moore SR, Pierce AM, Wilson DF. ‘Oral cancer’—the terminology dilemma. Oral Dis. 2009;6:191-193.
9. Gupta B, Kumar N, Johnson NW. Relationship of lifetime exposure to tobacco, alcohol and second hand tobacco smoke with upper aero-digestive tract cancers in India: a case-control study with a life-course perspective. Asian Pac J Cancer Prev. 2017;18:347-356.
10. Gupta B, Johnson NW. Emerging and established global life-style risk factors for cancer of the upper aero-digestive tract. Asian Pac J Cancer Prev. 2014;15:5983-5991.
11. Gupta B, Johnson NW. Systematic review and meta-analysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific. Prev Med. 2014;69:133-85.
12. Gupta B, Kumar N, Johnson NW. A risk factor-based model for upper aero-digestive tract cancers in India: predicting and validating the receiver operating characteristic curve. J Oral Pathol Med. 2017;46:465-471.
13. Institut National de Santé Publique. Enquête nationale de santé projet, 2005. Projet TAHINA Transition épidémiologique et système de santé. El Buir, Algeria: Ministère de la Santé, de la Population et de la Réforme Hospitalière; 2007.
14. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2015 (Country Profile). Geneva: World Health Organization; 2016.
15. Laouamri S, Hamdi-Cherif M, Sekfali N, Mohktari L, Kharchi R. Dietary risk factors of nasopharyngeal carcinoma in the Setif area in Algeria. Rev Epidémol Santé Publique. 2001;49:145-156.
16. Hassan MM, Spitz MR, Thomas MB, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer. 2008;123:1883-1891.
17. Feng BJ, Jalbouir M, Ayoub WB, et al. Dietary risk factors for nasopharyngeal carcinoma in Maghreb countries. Int J Cancer. 2007;121:1550-1555.
18. Sapkota A, Gajalakshmi V, Jetty DH, et al. Smokeless tobacco and increased risk of hypopharyngeal and laryngeal cancers: a multicentric case-control study from India. Int J Cancer. 2007;121:1793-1798.
19. Macfarlane TV, Macfarlane GJ, Oliver RJ, et al. The aetiology of upper aerodigestive tract cancers among young adults in Europe: the ARCADE study. Cancer Causes Control. 2010;21:2211-2221.
20. Long M, Fu Z, Li P, Nie Z. Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies. BMJ Open. 2017;7:e016582.
21. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
22. Filleul O, Preillon J, Crompton E, Lechien J, Saussez S. Incidence of head and neck cancers in Belgium: comparison with World Wide and French data. Bull Cancer. 2001;98:1173-1183.
23. International Agency for Research on Cancer. Tobacco Control: Reversal of Risk After Quitting Smoking (IARC Handbooks of Cancer Prevention). Lyon, France: IARC; 2007.
24. Ji X, Zhang W, Xie C, Wang B, Zhang G, Zhou F. Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int J Cancer. 2011;129:724-732.
25. Polesel J, Franceschi S, Talani M, et al. Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. Oral Oncol. 2011;47:541-545.
26. Herlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E366.
27. Xue WQ, Qin HD, Ruan HL, Shugart YY, Jia WH. Quantitative association of human papillomavirus with nasopharyngeal carcinoma in the People’s Republic of China: a comprehensive meta-analysis of studies conducted between 1979 and 2011. Am J Epidemiol. 2013;178:325-338.
28. Herrmann K, Niedobitek G. Epstein-Barr virus-associated carcinomas: facts and fiction. J Pathol. 2003;199:140-145.
29. Xu FH, Xiong D, Xu YF, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst. 2012;104:1396-1400.